The antitumor activity and the underlying mechanism of six novel curcumin derivatives (F1–F6) were evaluated in lung cancer cells. F5 was found to be the most potent derivative (IC₅₀ = 13.67 μM) compared to curcumin (IC₅₀ = 40.93 μM), with significant differences via MTT assay. A series of pharmacological experiments, including clone formation, wound healing, and transwell assay, reveal that F5 can inhibit lung cell proliferation and migration. Western blot and molecular docking studies demonstrate that the potential mechanism may relate to the regulation of the AKT/ERK/MMP9 signaling pathway. Therefore, curcumin derivative F5 can potentially be used for treating lung cancer.

在肺癌细胞中评价了 6 种新型姜黄素衍生物 （F1-F6） 的抗肿瘤活性和潜在机制。与姜黄素 （IC₅₀ = 40.93 μM） 相比，F5 是最有效的衍生物 （IC₅₀ = 40.93 μM），通过 MTT 测定存在显着差异。一系列药理实验，包括克隆形成、伤口愈合和 transwell 测定，表明 F5 可以抑制肺细胞增殖和迁移。Western blot 和分子对接研究表明，潜在机制可能与 AKT/ERK/MMP9 信号通路的调节有关。因此，姜黄素衍生物 F5 有可能用于治疗肺癌。